Clinical trials: Dendritic Cell
Breast Cancer, Triple Negative Breast Cancer
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant…
- Trial name
- NCT06435351
- Testing
- Leukapheresis, Dendritic Cell (DC) Vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
This is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC.
- Conditions
- Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02033616
- Testing
- AVOVA-1, MC
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aivita Biomedical, Inc.
Asthma
Non-Eosinophilic Biological Effects of IL-5
This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma.
- Trial name
- NCT06026202
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Imperial College London
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid…
- Trial name
- ABC123 (NCT03203369)
- Testing
- UCART123
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cellectis S.A.
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
- Conditions
- Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01239875
- Testing
- dendritic cell vaccine therapy, cryotherapy, pneumococcal polyvalent vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01826877
- Testing
- AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Lymphoma
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002553
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hematopoietic cell transplant (HCT).
- Trial name
- NCT02851056
- Testing
- Survivin Vaccine, Autologous Hematopoietic Cell Transplantation, Prevnar 13
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
The purpose of this study is to determine the safety and tolerability of the intranodal administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and pulsed with myelin peptides (tolDC-VitD3) in…
- Trial name
- TOLERVIT-MS (NCT02903537)
- Testing
- Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3), Interferon-beta
- Where
- 2 sites in Spain
- Volunteers
- 16 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Melanoma
Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy
Cancer cells make proteins called antigens that act as markers for the tumor cells. These antigens cannot cause the cancer itself. Special white blood cells, called T cells or T lymphocytes, recognize and respond to antigens.
- Trial name
- NCT00700167
- Testing
- dendritic cell vaccine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasms
Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2
We, the researchers at Hamilton Health Sciences, have developed a novel approach to cancer therapy using transfected dendritic cells (DCs) to generate enhanced immunity to defined tumor antigens.
- Trial name
- NCT00197522
- Testing
- CD34+ derived DCs
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Hamilton Health Sciences Corporation
Leukemia, Lymphoma
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00018954
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 5 sites in United States, Egypt and 1 more
- Sponsor
- National Institutes of Health Clinical Center (CC)
Type 1 Diabetes Mellitus
An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
This phase I trial investigates the side effects of PIpepTolDC vaccine in treating patients with type 1 diabetes who use insulin and don't have any other diabetes-related health complications.
- Trial name
- NCT04590872
- Testing
- Tolerogenic Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Solid Tumor
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
- Trial name
- DC-CIK (NCT04214717)
- Testing
- DC-CIK combined with Chemotherapy, Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yantai Yuhuangding Hospital
Glioblastoma, Glioma
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients…
- Conditions
- Glioblastoma, Glioma, Neoplasms, Neuroepithelial, Neuroectodermal Tumors
- Trial name
- NCT04388033
- Testing
- Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12, Temozolomide
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Squamous Cell Carcinoma
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
- Trial name
- NCT05317325
- Testing
- OCDC vaccine; NeoDC vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Lymphoma
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004908
- Testing
- cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
- Where
- United States
- Sponsor
- Northwestern University
Innate Immune Responses
Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells. PLASMACYTOKID
Differences in pDCs function related to gender have been demonstrated in adults but have never been addressed in children. Yet, differences in immune responses related to gender also exist in children, both in responses to…
- Trial name
- NCT02956980
- Testing
- Blood Plasmacytoid dendritic cells (pDCs) absolute number
- Where
- France
- Volunteers
- 78 people
- Sponsor
- University Hospital, Toulouse
Alzheimer Disease
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia…
- Trial name
- NCT05834296
- Testing
- ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alzamend Neuro, Inc.